For the correction of haemodynamic imbalances in low-perfusion circulatory insufficiency associated with myocardial infarction, trauma, septicaemia, cardiac failure and open heart surgery.
GlaxoSmithKline announced headline results from its second Phase III study with darapladib mesylate, SOLID-TIMI 52, evaluating the efficacy of its...
Sun Pharmaceutical Industries Ltd announced that one of its subsidiaries has received final approval from FDA for its Abbreviated New...